|
| Product Name
|
|
ABL1, Polyclonal Antibody
|
| Also Known As
|
|
ABL1 Antibody
|
| Product Synonym Names
|
|
ABL1; ABL; JTK7; bcr/abl; c-ABL; p150; v-abl
|
| Product Gene Name
|
|
|
[Similar Products]
|
| Research Use Only
|
|
For Research Use Only. Not for use in diagnostic procedures.
|
 TOP
|
|
| OMIM
|
|
189980
|
|
| Clonality
|
|
Polyclonal
|
| Isotype
|
|
IgG
|
| Host
|
|
Rabbit
|
| Species Reactivity
|
|
Human, Mouse, Rat
|
|
|
| Purity/Purification
|
|
Antigen affinity purification
|
| Concentration
|
|
1mg/mL (lot specific)
|
|
|
| Immunogen
|
|
C term -peptide of human ABL1
|
| Observed Molecular Weight: 123kDa
|
|
|
| Buffer
|
|
PBS with 0.02% sodium azide, 50% glycerol, pH7.3
|
| Santa Cruz Alternative
|
|
Potential replacement for Santa Cruz Biotechnology antibody catalog# sc-13076 / sc-887 / sc-131
|
|
|
| Preparation and Storage
|
|
Store at -20 degree C (regular) and -80 degree C (long term). Avoid freeze / thaw cycles.
|
| ISO Certification
|
|
Manufactured in an ISO 9001:2008 Certified Laboratory.
|
| Other Notes
|
|
Small volumes of anti-ABL1 antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
|
|
TOP
|
|
|
|
|
The c-Abl proto-oncogene encodes a nonreceptor protein tyrosine kinase that is ubiquitously expressed and highly conserved in metazoan evolution. c-Abl protein is distributed in both the nucleus and the cytoplasm of cells. It is implicated in regulating cell proliferation, differentiation, apoptosis, cell adhesion and stress responses (1-3). c-Abl kinase activity is increased in vivo by diverse physiological stimuli including integrin activation, PDGF stimulation and binding to c-Jun, Nck and RFX1 (2, 4). The in vivo mechanism of regulation of c-Abl kinase activity is not completely understood. Tyr245 is located in the linker region between the SH2 and catalytic domains. This positioning is conserved among Abl family members. Phosphorylation of Tyr245 is involved in the activation of c-Abl kinase (5). In addition, phosphorylation of Tyr412, which is located in the kinase activation loop of c-Abl, is required for kinase activity (6).
|
|
| Applications Tested/Suitable for anti-ABL1 antibody
|
|
Western Blot (WB)
|
|
|
| Western Blot (WB) of anti-ABL1 antibody
|
|
Western blot analysis of extracts of various cell lines, using ABL1 antibody.
|
|
|
| Testing Data #2 of anti-ABL1 antibody
|
|
|
|
TOP
|
|
| NCBI/Uniprot data below describe general gene information for ABL1. It may not necessarily be applicable to this product. |
| NCBI GI #
|
|
553164
|
| NCBI GeneID
|
|
25
|
| NCBI Accession #
|
|
AAA88012.1
|
[Other Products]
|
|
|
| UniProt Secondary Accession #
|
|
Q13869; Q13870; Q16133; Q17R61; Q45F09; A3KFJ3
|
[Other Products]
|
| UniProt Related Accession #
|
|
P00519
|
[Other Products]
|
| Molecular Weight
|
|
124,955 Da
|
|
TOP
|
| NCBI Official Full Name
|
|
ABL1, partial
|
| NCBI Official Synonym Full Names
|
|
ABL proto-oncogene 1, non-receptor tyrosine kinase
|
| NCBI Official Symbol
|
|
ABL1
|
[Similar Products]
|
| NCBI Official Synonym Symbols
|
|
ABL; JTK7; p150; c-ABL; v-abl; c-ABL1; bcr/abl
|
[Similar Products]
|
| NCBI Protein Information
|
|
tyrosine-protein kinase ABL1; Abelson tyrosine-protein kinase 1; bcr/c-abl oncogene protein; c-abl oncogene 1, receptor tyrosine kinase; proto-oncogene c-Abl; proto-oncogene tyrosine-protein kinase ABL1; v-abl Abelson murine leukemia viral oncogene homolog 1
|
| UniProt Protein Name
|
|
Tyrosine-protein kinase ABL1
|
| UniProt Synonym Protein Names
|
|
Abelson murine leukemia viral oncogene homolog 1; Abelson tyrosine-protein kinase 1; Proto-oncogene c-Abl; p150
|
| Protein Family
|
|
Tyrosine-protein kinase
|
| UniProt Gene Name
|
|
ABL1
|
[Similar Products]
|
| UniProt Synonym Gene Names
|
|
ABL; JTK7
|
[Similar Products]
|
| UniProt Entry Name
|
|
ABL1_HUMAN
|
|
|
| NCBI Summary for ABL1
|
|
This gene is a protooncogene that encodes a protein tyrosine kinase involved in a variety of cellular processes, including cell division, adhesion, differentiation, and response to stress. The activity of the protein is negatively regulated by its SH3 domain, whereby deletion of the region encoding this domain results in an oncogene. The ubiquitously expressed protein has DNA-binding activity that is regulated by CDC2-mediated phosphorylation, suggesting a cell cycle function. This gene has been found fused to a variety of translocation partner genes in various leukemias, most notably the t(9;22) translocation that results in a fusion with the 5' end of the breakpoint cluster region gene (BCR; MIM:151410). Alternative splicing of this gene results in two transcript variants, which contain alternative first exons that are spliced to the remaining common exons. [provided by RefSeq, Aug 2014]
|
|
|
| UniProt Comments for ABL1
|
|
Abl: an ubiquitously expressed and highly conserved proto-oncogenic tyrosine kinase. c-Abl protein is distributed in both the nucleus and the cytoplasm of cells. Negatively regulated by its SH3 domain, and deletion of the SH3 domain turns ABL1 into an oncogene. It has been implicated in regulation of cell proliferation, differentiation, apoptosis, cell adhesion and stress response. The Philadephia chromosome translocation t(9;22)(q34;q11) creates a Bcr-Abl fusion protein, responsible for 90% of chronic myelogenous leukemia (CML) and ~25% of acute lymphoblastic leukemia (ALL). Inhibitors: Gleevec (imatinib, Glivec), Dasatinib. Two alternatively-spliced isoforms have been described.
Protein type: Oncoprotein; Kinase, protein; EC 2.7.10.2; Protein kinase, TK; Protein kinase, tyrosine (non-receptor); TK group; Abl family
Chromosomal Location of Human Ortholog: 9q34.1
Cellular Component: nucleoplasm; extrinsic to internal side of plasma membrane; nuclear membrane; mitochondrion; perinuclear region of cytoplasm; leading edge; cytoplasm; nucleolus; nucleus; cytosol; actin cytoskeleton
Molecular Function: protein C-terminus binding; actin monomer binding; non-membrane spanning protein tyrosine kinase activity; magnesium ion binding; protein kinase activity; actin filament binding; protein binding; DNA binding; syntaxin binding; protein-tyrosine kinase activity; manganese ion binding; mitogen-activated protein kinase binding; nicotinate-nucleotide adenylyltransferase activity; SH3 domain binding; ATP binding; receptor binding
Biological Process: DNA damage induced protein phosphorylation; positive regulation of apoptosis; cerebellum morphogenesis; negative regulation of BMP signaling pathway; elevation of cytosolic calcium ion concentration; transitional one stage B cell differentiation; B cell receptor signaling pathway; regulation of endocytosis; negative regulation of mitotic cell cycle; neuromuscular process controlling balance; cell cycle arrest; positive regulation of oxidoreductase activity; spleen development; mitosis; positive regulation of I-kappaB kinase/NF-kappaB cascade; negative regulation of I-kappaB kinase/NF-kappaB cascade; positive regulation of peptidyl-tyrosine phosphorylation; muscle cell differentiation; DNA damage response, signal transduction resulting in induction of apoptosis; positive regulation of osteoblast proliferation; negative regulation of ubiquitin-protein ligase activity; autophagy; response to oxidative stress; actin cytoskeleton organization and biogenesis; axon guidance; peptidyl-tyrosine phosphorylation; alpha-beta T cell differentiation; platelet-derived growth factor receptor signaling pathway; mitochondrial depolarization; positive regulation of mitotic cell cycle; Bergmann glial cell differentiation; regulation of transcription, DNA-dependent; collateral sprouting; cell differentiation; B cell proliferation during immune response; regulation of cell adhesion; epidermal growth factor receptor signaling pathway; cell migration; mismatch repair; thymus development; B-1 B cell homeostasis; activated T cell proliferation; DNA damage response, signal transduction; protein modification process; regulation of cell proliferation; microspike biogenesis; positive regulation of muscle cell differentiation; innate immune response; regulation of autophagy; positive regulation of release of sequestered calcium ion into cytosol; negative regulation of cell-cell adhesion; blood coagulation; response to DNA damage stimulus
Disease: Leukemia, Chronic Myeloid
|
|
TOP
|
|
| Research Articles on ABL1
|
|
1. Although BCR-ABL induces STAT5-tyrosine phosphorylation independent of JAK2-kinase activity, BCR-ABL is less efficient in inducing active STAT5A:STAT5B-heterodimerization than IL-3.
|
|
TOP
|
| Precautions
|
|
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
|
| Disclaimer
|
|
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
|
|
TOP
|
|
| Products associated with anti-ABL1 antibody | Pathways associated with anti-ABL1 antibody |
|
|
|
| Diseases associated with anti-ABL1 antibody | Organs/Tissues associated with anti-ABL1 antibody |
| Disease Name |
Pubmed Publications |
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive Antibodies |
>414 publications with ABL1 and Leukemia, Myelogenous, Chronic, BCR-ABL Positive |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma Antibodies |
>169 publications with ABL1 and Precursor Cell Lymphoblastic Leukemia-Lymphoma |
| Cell Transformation, Neoplastic Antibodies |
>69 publications with ABL1 and Cell Transformation, Neoplastic |
| Carcinogenesis Antibodies |
>66 publications with ABL1 and Carcinogenesis |
| Anemia Antibodies |
>22 publications with ABL1 and Anemia |
| Neoplasms, Experimental Antibodies |
>18 publications with ABL1 and Neoplasms, Experimental |
| Disease Models, Animal Antibodies |
>16 publications with ABL1 and Disease Models, Animal |
| Cardiovascular Diseases Antibodies |
>13 publications with ABL1 and Cardiovascular Diseases |
| Nervous System Diseases Antibodies |
>11 publications with ABL1 and Nervous System Diseases |
| Adenocarcinoma Antibodies |
>8 publications with ABL1 and Adenocarcinoma |
|
|
|
|
|
TOP
|
Antibody 
